Maikou Medicine-B (2335.HK) climbed 5% during regular trading to 38.88 HKD, hitting an all-time high with turnover exceeding 38.87 million HKD.

The company officially listed on the Main Board of HKEX on June 24, 2026, becoming the first Northwest innovator pharmaceutical firm under Rule 18A. IPO price was set at 18.2 HKD; maiden-day close reached 36.9 HKD, marking a 103% surge.

Hong Kong retail subscription achieved approximately 1,181 times oversubscription, while dark pool trading previously spiked over 95%. The company focuses on peptide drug development; lead product MT1013 is currently in Phase III clinical trials with no commercial revenue yet realized.